SARMs: what they are, how they differ from steroids, and what the evidence shows

Selective androgen receptor modulators (SARMs) are a class of compounds developed beginning in the 1990s with a specific medical goal: activating the androgen receptor, the same receptor testosterone acts on, in a way that would build muscle and bone while sparing tissues like the prostate and skin from the effects associated with anabolic steroid use. The intended clinical use was treating muscle wasting associated with cancer, HIV/AIDS, and aging, conditions where preserving lean mass and function matters and where testosterone's broader tissue effects are considered an unwanted trade-off.

The proposed mechanism is receptor selectivity. Testosterone activates androgen receptors throughout the body and is also converted into other active hormones: into dihydrotestosterone (DHT) in tissues like skin and the prostate, and into estrogen via the aromatase enzyme in fat and other tissues. Those conversions are part of why testosterone use is associated with effects like hair loss, prostate growth, and gynecomastia. SARMs were designed as non-steroidal molecules that bind the androgen receptor with a conformation intended to produce different effects in muscle and bone tissue than in the prostate or skin, without aromatizing into estrogen. In practice, tissue selectivity has been shown to be dose-dependent and incomplete in trials, meaning the separation between desired and undesired effects narrows as dose increases.

The best-studied compound in this class is enobosarm (also known as ostarine or GTx-024, and sold under research labels as MK-2866). It reached randomized, placebo-controlled Phase 3 trials, the POWER trials, evaluating enobosarm in patients starting first-line chemotherapy for non-small-cell lung cancer, with lean body mass and physical function (stair-climb power) as co-primary endpoints [1]. This is Moderate Human Evidence: the trials were large, randomized, and placebo-controlled, which is a materially stronger evidence base than exists for almost any other compound discussed in this category, but the trials did not meet their pre-specified primary efficacy endpoints, and enobosarm has not received FDA approval for any indication [1]. Other SARMs discussed in non-clinical or research contexts, including ligandrol (LGD-4033), testolone (RAD-140), and andarine (S4), have little to no equivalent randomized human trial data; what is publicly available is largely limited to smaller early-phase studies, case reports, or preclinical research, which is Early Human Evidence to Mechanistic Research depending on the specific compound.

Documented side effects associated with SARM use, drawn from clinical trial data and case reports, include suppression of endogenous testosterone production, which is a consistent finding across the class because activating androgen receptors provides negative feedback to the hypothalamic-pituitary-gonadal axis regardless of tissue selectivity elsewhere. Case reports have described elevated liver enzymes and hepatotoxicity associated with SARM use, including reports specifically implicating RAD-140, and adverse shifts in lipid profiles (lower HDL, higher LDL) have been reported in trial and case data [2]. Long-term cancer risk from SARM use has not been established either way in humans, which reflects an absence of the long-duration studies that would be needed to assess it, not evidence of safety.

It is worth being specific about how the compounds discussed in research and forum contexts differ from each other, since they are often treated as interchangeable when their evidence base is not. Ligandrol (LGD-4033) has undergone small, short-duration human studies looking primarily at pharmacokinetics and suppression of testosterone and other hormones, generally in healthy volunteers over a few weeks, rather than the larger, longer efficacy trials enobosarm went through; those studies consistently found dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and total testosterone. Testolone (RAD-140) has little published human trial data at all; most of what is publicly documented comes from case reports, several of which describe drug-induced liver injury in people using it outside any clinical trial setting. Andarine (S4) was discontinued from further pharmaceutical development in part because of reported visual disturbances (difficulty adapting to darkness, yellow-tinted vision) observed during early testing, an effect attributed to the compound's action on other receptors in the eye beyond the androgen receptor. None of these three compounds carries anything close to the human evidence base enobosarm has, despite being discussed in similar terms in non-clinical contexts.

Regulatory status is unambiguous. No SARM is FDA-approved for human use for any indication. The World Anti-Doping Agency (WADA) and the U.S. Anti-Doping Agency (USADA) classify SARMs as prohibited substances under the anabolic agents category, and USADA's public resources describe SARMs and their metabolites as detectable in urine for extended periods, in some cases weeks to months, following use [3]. The FDA has issued warning letters to companies marketing SARMs for human consumption, and products labeled "research use only" or "not for human consumption" do not carry any regulatory approval or safety review despite that labeling [4].

The comparison to anabolic-androgenic steroids that is often raised in discussion of SARMs deserves a direct answer, since SARMs are frequently framed as a lower-risk alternative. SARMs do not aromatize into estrogen the way testosterone does, which removes one specific pathway (direct estrogen conversion) associated with steroid-related gynecomastia. That does not mean SARM use avoids hormonal disruption altogether: suppression of the body's own testosterone production is a consistent, well-documented finding across the SARMs with human data, and estrogen-related effects can still occur afterward as a rebound phenomenon once natural testosterone production is suppressed and estrogen becomes comparatively dominant. In practice, the claim that SARMs are meaningfully safer than steroids because they are non-aromatizing addresses one narrow mechanism while leaving the broader hormonal suppression risk, which several forum and marketing sources understate, unaddressed.

Independent testing of products sold as SARMs has repeatedly found discrepancies between label claims and actual contents, including underdosed or overdosed product, the wrong compound entirely, and products containing substances other than what was labeled. This mirrors the broader pattern the World Health Organization documents for substandard and falsified medical products sold outside regulated pharmacy channels generally [5], and it means label-stated dose or identity cannot be assumed accurate without independent verification.

The muscle-wasting indication these trials targeted is also a useful reminder of what a compound being studied does not automatically mean. The POWER trials tested enobosarm specifically as a supportive therapy in a serious, medically supervised context, cancer-related muscle wasting during chemotherapy, using a fixed dose over a defined 147-day period with close clinical monitoring throughout. That is a substantially different situation from open-ended, unsupervised use at self-selected doses for physique or performance goals in people who are not undergoing chemotherapy, and the trial's own negative result for its primary endpoints (lean body mass and physical function) should temper claims made about enobosarm's effectiveness even in the population and context where it has actually been tested most rigorously.

The main limitations to note: the strongest human evidence available (the enobosarm POWER trials) comes from a specific, medically vulnerable population (lung cancer patients on chemotherapy) using a specific dose and duration, and did not demonstrate the intended benefit even in that closely monitored setting; it does not describe outcomes in generally healthy adults using these compounds for physique or performance goals over different doses and durations. For most other SARMs in common circulation, human safety and efficacy data is materially thinner than for enobosarm, consisting mostly of case reports rather than controlled trials, which limits how precisely their risk profile can be characterized.

In practical terms, the combination of incomplete tissue selectivity at higher doses, consistent suppression of natural testosterone production, documented case reports of liver enzyme elevation, unresolved long-term cancer risk, no FDA approval for any use, and well-documented product-identity risk in the unregulated market means SARMs do not have an evidence base supporting a favorable risk profile relative to other unapproved compounds. This article describes what has and has not been studied; it is not guidance on using SARMs and does not substitute for discussing hormonal health, including testosterone suppression and recovery, with a clinician.